Chiron Patent For HCV Nucleic Acid Testing Upheld

Chiron Corporation has announced that the European Patent Office Technical Board of Appeals upheld the validity of Chiron’s European HCV Patent No. 0 318 216 in amended form. The final ‘216 patent contains broad claims that cover nucleic acid testing (NAT) for hepatitis C virus (HCV) detection and the manufacture, use or sale of such Read more about Chiron Patent For HCV Nucleic Acid Testing Upheld[…]

Chiron Licenses Acute Rejection Agent From Novartis

Chiron has acquired exclusive worldwide development and commercialization rights to aerosolized cyclosporine (AcsA), an agent with potential in lung transplant acute rejection from Novartis. Clinical studies have been conducted in about 100 lung transplant patients at the University of Pittsburgh. Terms of agreement were not disclosed. Chiron Corporation, headquartered in Emeryville, California, has a strategic Read more about Chiron Licenses Acute Rejection Agent From Novartis[…]